NA
ALNY icon

NewEdge Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

NewEdge Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$774K Buy
2,570
+254
+11% +$76.6K ﹤0.01% 1835
2026
Q1 		$766K Sell
2,316
-701
-23% -$239K ﹤0.01% 1667
2025
Q4 		$1.2M Buy
3,017
+1,493
+98% +$661K ﹤0.01% 1376
2025
Q3 		$695K Buy
1,524
+820
+116% +$334K ﹤0.01% 1619
2025
Q2 		$229K Buy
704
+703
+70,300% +$195K ﹤0.01% 2153
2025
Q1 		$270 Sell
1
-972
-100% -$250K ﹤0.01% 3778
2024
Q4 		$229K Buy
973
+972
+97,200% +$256K ﹤0.01% 2021
2024
Q3 		$275 Sell
1
-994
-100% -$259K ﹤0.01% 3662
2024
Q2 		$242K Buy
995
+977
+5,428% +$154K ﹤0.01% 1828
2024
Q1 		$2.69K Buy
18
+14
+350% +$2.33K ﹤0.01% 3314
2023
Q4 		$765 Hold
4
– – ﹤0.01% 3497
2023
Q3 		$708 Hold
4
– – ﹤0.01% 3215
2023
Q2 		$760 Hold
4
– – ﹤0.01% 3281
2023
Q1 		$801 Sell
4
-60
-94% -$12.6K ﹤0.01% 3187
2022
Q4 		$13.8K Buy
+64
New +$13.7K ﹤0.01% 2263

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's ALNY Position: Q2 2026 in Review

NewEdge Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, buying an estimated $76.6K and bringing the position to 2,570 shares worth $774K. The position accounts for ﹤0.01% of the portfolio, ranked #1835.

NewEdge Advisors first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.2M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • NewEdge Advisors held 2,570 shares of Alnylam Pharmaceuticals worth $774K as of Q2 2026.
  • NewEdge Advisors bought 254 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $76.6K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1835 holding.
  • NewEdge Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • NewEdge Advisors's Alnylam Pharmaceuticals position peaked at $1.2M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.